What are the limitations of the febrile neutropaenia risk mascc?

While the febrile neutropaenia risk mascc is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the febrile neutropaenia risk mascc to ensure safe bedside use and optimal diagnostic accuracy.

How does the febrile neutropaenia risk mascc compare to other Hematology scores?

The febrile neutropaenia risk mascc is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the febrile neutropaenia risk mascc free to use?

Yes. OpiCalc provides the febrile neutropaenia risk mascc completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

Febrile Neutropaenia Risk (MASCC)

Febrile Neutropaenia: Goal is to identify low-risk outpatients (Score ≥ 21). High-risk patients (Score < 21) mandate inpatient IV antibiotics.

1. Burden of Febrile Illness

2. Clinical Modifiers

MASCC Risk Score

5

Risk Class

High Risk

Clinical Guidance

Mandates Inpatient Admission & IV Antibiotics.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Identifying patients with febrile neutropaenia who are at a low risk for medical complications.

Selecting candidates for outpatient antibiotic therapy or early hospital discharge.

Applying to adult oncology patients receiving myelosuppressive chemotherapy.

Temperature Threshold

Febrile neutropaenia is typically defined as a single oral temperature of > 38.3°C (101°F) or > 38.0°C (100.4°F) sustained for one hour, in a patient with an ANC < 500 cells/mm³.

Section 2

Formula & Logic

Predictor Points (Weighted)

Criterion	Points
Burden of illness: No or mild symptoms	5
Burden of illness: Moderate symptoms	3
No hypotension (SBP > 90 mmHg)	5
No COPD (Chronic Obstructive Pulmonary Disease)	4
Solid tumour OR no previous fungal infection in hematologic malignancy	4
No dehydration	3
Outpatient status at fever onset	3
Age < 60 years	2

Interpretation

≥ 21 points: Low-risk (Likelihood of complications < 6%).

< 21 points: High-risk (Mandates inpatient hospitalization).

Section 3

Pearls/Pitfalls

Symptoms vs. Acuity

The "Burden of Illness" point is the most subjective and should be evaluated based on the clinician's overall impression of the patient's clinical distress. Even if a patient scores 21, if they appear clinically unstable, admission remains the standard of care.

Primary Strategy

Most Low-Risk (MASCC ≥ 21) outpatients can be managed safely with oral antibiotics (e.g., Ciprofloxacin + Amoxicillin/Clavulanate) following a short period of observation (2-24h).

Section 4

Evidence Appraisal

Primary Strategy

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Klastersky J et al. • Journal of Clinical Oncology. 2000;18(16):3038-51.

View Source

Section 5

Literature

Organization

Developed by MASCC (Multinational Association for Supportive Care in Cancer), the score has been validated globally across multiple oncology settings.

Last Comprehensive Review: 2026

Related Hematology Tools

Anti-Xa Monitoring Interpreter

Perioperative Anticoagulation Bridging

Time in Therapeutic Range

Fibrinogen Replacement

Blood Volume Calculator

Expected Hb Rise per RBC Unit

Platelet Increment Calculator

TACO Risk Score

MTP Activation Criteria

ABC Score

Have feedback about this calculator?Let us know.

Febrile Neutropaenia Risk (MASCC)

Febrile Neutropaenia: Goal is to identify low-risk outpatients (Score ≥ 21). High-risk patients (Score < 21) mandate inpatient IV antibiotics.

1. Burden of Febrile Illness

2. Clinical Modifiers

MASCC Risk Score

5

Risk Class

High Risk

Clinical Guidance

Mandates Inpatient Admission & IV Antibiotics.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Identifying patients with febrile neutropaenia who are at a low risk for medical complications.

Selecting candidates for outpatient antibiotic therapy or early hospital discharge.

Applying to adult oncology patients receiving myelosuppressive chemotherapy.

Temperature Threshold

Febrile neutropaenia is typically defined as a single oral temperature of > 38.3°C (101°F) or > 38.0°C (100.4°F) sustained for one hour, in a patient with an ANC < 500 cells/mm³.

Section 2

Formula & Logic

Predictor Points (Weighted)

Criterion	Points
Burden of illness: No or mild symptoms	5
Burden of illness: Moderate symptoms	3
No hypotension (SBP > 90 mmHg)	5
No COPD (Chronic Obstructive Pulmonary Disease)	4
Solid tumour OR no previous fungal infection in hematologic malignancy	4
No dehydration	3
Outpatient status at fever onset	3
Age < 60 years	2

Interpretation

≥ 21 points: Low-risk (Likelihood of complications < 6%).

< 21 points: High-risk (Mandates inpatient hospitalization).

Section 3

Pearls/Pitfalls

Symptoms vs. Acuity

Primary Strategy

Most Low-Risk (MASCC ≥ 21) outpatients can be managed safely with oral antibiotics (e.g., Ciprofloxacin + Amoxicillin/Clavulanate) following a short period of observation (2-24h).

Section 4

Evidence Appraisal

Primary Strategy

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Klastersky J et al. • Journal of Clinical Oncology. 2000;18(16):3038-51.

View Source

Section 5

Literature

Organization

Developed by MASCC (Multinational Association for Supportive Care in Cancer), the score has been validated globally across multiple oncology settings.

Last Comprehensive Review: 2026

Related Hematology Tools

Anti-Xa Monitoring Interpreter

Perioperative Anticoagulation Bridging

Time in Therapeutic Range

Fibrinogen Replacement

Blood Volume Calculator

Expected Hb Rise per RBC Unit

Platelet Increment Calculator

TACO Risk Score

MTP Activation Criteria

ABC Score

Have feedback about this calculator?Let us know.